Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Research & Development (2020 - 2025)

Historic Research & Development for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $22.4 million.

  • Caribou Biosciences' Research & Development fell 2636.34% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.1 million, marking a year-over-year decrease of 1136.16%. This contributed to the annual value of $130.2 million for FY2024, which is 1613.03% up from last year.
  • As of Q3 2025, Caribou Biosciences' Research & Development stood at $22.4 million, which was down 2636.34% from $27.7 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Research & Development ranged from a high of $35.5 million in Q1 2025 and a low of $10.2 million during Q1 2021
  • In the last 5 years, Caribou Biosciences' Research & Development had a median value of $25.7 million in 2022 and averaged $24.4 million.
  • As far as peak fluctuations go, Caribou Biosciences' Research & Development soared by 15619.74% in 2021, and later crashed by 2636.34% in 2025.
  • Quarter analysis of 5 years shows Caribou Biosciences' Research & Development stood at $15.1 million in 2021, then skyrocketed by 70.31% to $25.7 million in 2022, then rose by 21.54% to $31.3 million in 2023, then dropped by 2.61% to $30.5 million in 2024, then decreased by 26.47% to $22.4 million in 2025.
  • Its Research & Development stands at $22.4 million for Q3 2025, versus $27.7 million for Q2 2025 and $35.5 million for Q1 2025.